SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

L773:1071 7323
 

Sökning: L773:1071 7323 > Predictors of weigh...

Predictors of weight loss in adults with topiramate-treated epilepsy.

Ben-Menachem, Elinor, 1945 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för klinisk neurovetenskap, Sektionen för kliniska nervsjukdomar,Institute of Clinical Neurosciences, Section of Neurological Diseases
Axelsen, Mette, 1965 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för internmedicin,Institute of Internal Medicine, Dept of Medicine
Hellebö Johanson, Else, 1969 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för internmedicin,Institute of Internal Medicine, Dept of Medicine
visa fler...
Stagge, Anna (författare)
Smith, Ulf, 1943 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för internmedicin,Institute of Internal Medicine, Dept of Medicine
visa färre...
 (creator_code:org_t)
2003
2003
Engelska.
Ingår i: Obesity research. - 1071-7323. ; 11:4, s. 556-62
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • OBJECTIVE: We examined predictors of weight loss with topiramate, an anticonvulsant associated with weight loss in adults. RESEARCH METHODS AND PROCEDURES: In this uncontrolled, prospective clinical trial, topiramate was added to existing anticonvulsants in adults (40 to 110 kg) with partial-onset seizures. Primary measurements were change from baseline weight after 3 months and 1 year in patients completing 1 year of topiramate treatment (N = 38). Physiological and metabolic measures were analyzed for correlation with weight loss during topiramate treatment. RESULTS: In patients who completed 1 year of topiramate treatment, baseline weight was reduced in 82% at 3 months and in 86% at 1 year. Mean body weight was reduced 3.0 kg (3.9% of baseline) at 3 months and 5.9 kg (7.3%) at 1 year. In obese patients [body mass index (BMI) >/= 30 kg/m(2)], mean weight loss was 4.2 kg (4.3%) at 3 months and 10.9 kg (11.0%) at 1 year. Weight loss was primarily caused by reduction in body fat mass. For all patients, weight loss at 3 months correlated most strongly with reduced caloric intake (p = 0.02). At 1 year, caloric intake had returned to baseline levels; weight loss correlated most strongly with higher baseline BMI (p = 0.0007). DISCUSSION: Our results suggest that weight loss occurs in most adults treated with topiramate and is sustained for at least 1 year. Reduced caloric intake may account, in part, for weight loss during early treatment. The pattern of weight loss differs according to baseline BMI, with obese patients experiencing greater weight loss during continued therapy.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Nyckelord

Adult
Anticonvulsants
adverse effects
therapeutic use
Blood Glucose
analysis
Body Composition
drug effects
Body Mass Index
Cholesterol
blood
Energy Intake
Epilepsy
drug therapy
Female
Fructose
adverse effects
analogs & derivatives
therapeutic use
Glucose Tolerance Test
Humans
Leptin
blood
Male
Middle Aged
Obesity
physiopathology
Prospective Studies
Regression Analysis
Weight Loss
drug effects

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy